Department of Haematology, Manchester University Hospitals, Oxford Road, Manchester, UK.
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
J Thromb Haemost. 2023 Jul;21(7):1737-1740. doi: 10.1016/j.jtha.2023.03.016. Epub 2023 Mar 25.
Hemophilia is classified into mild, moderate, and severe based on coagulation factor activity levels. Factor replacement and prophylaxis regimens in persons with hemophilia have helped to reduce bleeding and its related complications. With several newer treatments, some already approved and others soon to be, there may be a need to consider health-related quality of life in addition to bleed prevention as the goals of providing comprehensive care to persons with hemophilia. In this article, we discussed the reasons why such an approach may be relevant and call for the International Society of Thrombosis and Haemostasis to revisit the current classification of hemophilia.
根据凝血因子活性水平，血友病可分为轻度、中度和重度。血友病患者的因子替代和预防治疗方案有助于减少出血及其相关并发症。随着一些新的治疗方法的出现，其中一些已经获得批准，其他的也即将获批，因此，在为血友病患者提供全面护理时，除了预防出血外，可能还需要考虑与健康相关的生活质量。在本文中，我们讨论了这种方法可能相关的原因，并呼吁国际血栓与止血学会重新审视当前的血友病分类。
